IL108372A - 1-(2-AMINO-6- DIPHENYLETHYLAMINO-9H- PURIN-9-YL)-1- DEOXY-b-D- RIBOFURANURONAMIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

1-(2-AMINO-6- DIPHENYLETHYLAMINO-9H- PURIN-9-YL)-1- DEOXY-b-D- RIBOFURANURONAMIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
IL108372A
IL108372A IL108372A IL10837294A IL108372A IL 108372 A IL108372 A IL 108372A IL 108372 A IL108372 A IL 108372A IL 10837294 A IL10837294 A IL 10837294A IL 108372 A IL108372 A IL 108372A
Authority
IL
Israel
Prior art keywords
ethyl
amino
deoxy
ribofuranuronamide
purin
Prior art date
Application number
IL108372A
Other languages
English (en)
Other versions
IL108372A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL108372A0 publication Critical patent/IL108372A0/xx
Publication of IL108372A publication Critical patent/IL108372A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL108372A 1993-01-20 1994-01-19 1-(2-AMINO-6- DIPHENYLETHYLAMINO-9H- PURIN-9-YL)-1- DEOXY-b-D- RIBOFURANURONAMIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IL108372A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939301000A GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds

Publications (2)

Publication Number Publication Date
IL108372A0 IL108372A0 (en) 1994-04-12
IL108372A true IL108372A (en) 1998-06-15

Family

ID=10728948

Family Applications (1)

Application Number Title Priority Date Filing Date
IL108372A IL108372A (en) 1993-01-20 1994-01-19 1-(2-AMINO-6- DIPHENYLETHYLAMINO-9H- PURIN-9-YL)-1- DEOXY-b-D- RIBOFURANURONAMIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (29)

Country Link
US (2) US5925624A (OSRAM)
EP (1) EP0680488B1 (OSRAM)
JP (1) JP3768232B2 (OSRAM)
KR (1) KR960700261A (OSRAM)
CN (1) CN1043997C (OSRAM)
AP (1) AP457A (OSRAM)
AT (1) ATE164849T1 (OSRAM)
AU (1) AU679714B2 (OSRAM)
CA (1) CA2153688A1 (OSRAM)
CZ (1) CZ187995A3 (OSRAM)
DE (1) DE69409503T2 (OSRAM)
DK (1) DK0680488T3 (OSRAM)
EC (1) ECSP941104A (OSRAM)
ES (1) ES2117249T3 (OSRAM)
FI (1) FI953489L (OSRAM)
GB (1) GB9301000D0 (OSRAM)
HU (1) HU211914A9 (OSRAM)
IL (1) IL108372A (OSRAM)
IS (1) IS4121A (OSRAM)
NO (1) NO305603B1 (OSRAM)
NZ (1) NZ259880A (OSRAM)
PE (1) PE54194A1 (OSRAM)
PL (1) PL309975A1 (OSRAM)
RU (1) RU2129561C1 (OSRAM)
SI (1) SI9400021A (OSRAM)
SK (1) SK281229B6 (OSRAM)
TW (1) TW267168B (OSRAM)
WO (1) WO1994017090A1 (OSRAM)
ZA (1) ZA94335B (OSRAM)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0828740T1 (en) * 1995-05-30 2001-12-31 Aventis Pharma Sa 2-azabicyclo(2.2.1)heptane derivatives, preparation and application thereof
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3861413B2 (ja) * 1997-11-05 2006-12-20 ソニー株式会社 情報配信システム、情報処理端末装置、携帯端末装置
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
WO1999043676A2 (en) * 1998-02-26 1999-09-02 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
PL204628B1 (pl) 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
HRP20000894A2 (en) 1998-06-23 2001-12-31 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
RU2258071C2 (ru) * 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CA2394654A1 (en) 1999-12-17 2001-06-21 Manfred Weigele Proton pump inhibitors
CN1440408B (zh) * 2000-04-25 2012-07-18 艾科斯有限公司 人磷脂酰肌醇3-激酶δ的抑制剂
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1939203B1 (en) * 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
ES2301659T3 (es) * 2001-07-06 2008-07-01 Topigen Pharmaceuticals Inc. Metodos para aumentar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos.
US6825349B2 (en) * 2001-11-09 2004-11-30 Cv Therapeutics Inc. A2B adenosine receptor antagonists
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6924271B2 (en) 2001-11-27 2005-08-02 Anadys Pharmaceuticals, Inc. 3-β-D-ribofuranosylthiazolo[4-5-d]pyridimine nucleosides and uses thereof
ATE446298T1 (de) 2001-11-30 2009-11-15 Osi Pharm Inc Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
ES2237234B1 (es) * 2002-08-02 2006-11-01 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
AU2003263846B2 (en) * 2002-08-15 2009-12-17 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0328319D0 (en) * 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Improved synthesis of 2-substituted adenosines
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DK2612862T3 (en) 2004-05-13 2016-12-05 Icos Corp Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
DK1758596T3 (da) * 2004-05-26 2010-07-26 Inotek Pharmaceuticals Corp Purinderivater som adenosin-A1-receptoragonister og fremgangsmåder til anvendelse deraf
FR2874014B1 (fr) * 2004-08-03 2010-05-14 Univ Paris Descartes Analogues d'aminoglycosides, leur utilisation et leur synthese
ES2450929T3 (es) 2004-10-29 2014-03-25 Topigen Pharmaceuticals Inc. Oligonucleótidos antisentido para tratar la alergia y la proliferación de las células neoplásicas
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DK2561872T3 (en) 2004-12-17 2014-12-08 Anadys Pharmaceuticals Inc 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED 3H-OXAZOLO- [4,5-d] PYRIMIDIN-2-ON COMPOUNDS AND PRODRUGS THEREOF
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
DE602006015700D1 (de) 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
US7528115B2 (en) 2006-07-18 2009-05-05 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
US8796241B2 (en) 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
ES2331867B1 (es) * 2008-07-17 2010-10-27 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EP3427739A1 (en) 2008-11-13 2019-01-16 Gilead Calistoga LLC Therapies for hematologic malignancies
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
AU2010239312A1 (en) 2009-04-20 2011-11-10 Gilead Calistoga Llc Methods of treatment for solid tumors
WO2011011550A1 (en) 2009-07-21 2011-01-27 Calistoga Pharmaceuticals Inc. Treatment of liver disorders with pi3k inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012003709B1 (pt) 2009-08-17 2021-05-18 Intellikine Llc compostos heterocíclicos e usos dos mesmos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
RU2012132278A (ru) 2010-01-12 2014-02-20 Ф. Хоффманн-Ля Рош Аг Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
CA2864305C (en) 2012-03-05 2021-02-16 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
PL2822954T3 (pl) 2012-12-21 2016-09-30 Policykliczne związki karbamoilopirydonu i ich farmaceutyczne zastosowanie
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
NO2865735T3 (OSRAM) 2013-07-12 2018-07-21
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
PL3083630T3 (pl) 2013-12-20 2020-02-28 Gilead Calistoga Llc Sposoby otrzymywania inhibitorów 3-kinazy fosfatydyloinozytolu
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (OSRAM) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
CN109563238B (zh) * 2016-08-10 2021-08-27 三键有限公司 环氧树脂组合物以及含有其的导电性胶粘剂
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
WO2019152977A2 (en) 2018-02-05 2019-08-08 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN119798352B (zh) * 2024-01-15 2025-11-11 中国医学科学院药物研究所 化合物yzg-331的晶型及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
CA1239397A (en) * 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
WO1985004882A1 (en) * 1984-04-18 1985-11-07 Nelson Research And Development Company N-6 substituted adenosine derivatives as cardiac vasodilators
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4757747A (en) * 1986-04-08 1988-07-19 Vickers, Incorporated Power transmission
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
PT86660B (pt) * 1987-02-04 1992-02-28 Ciba Geigy Ag Processo para a preparacao de derivados de adenosina-5'-carboxamida
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
DE3810551A1 (de) * 1987-04-06 1988-11-03 Sandoz Ag Neue ribofuranuronsaeure-derivate
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
ATE128141T1 (de) * 1988-03-16 1995-10-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
CA2028002A1 (en) * 1989-10-19 1991-04-20 Daniel P. Becker Method of treating gastrointestinal motility disorders
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
DE4025879A1 (de) * 1990-08-16 1992-02-20 Sandoz Ag Neue adenosin derivate, deren herstellung und verwendung
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
EP0708781B1 (en) * 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists

Also Published As

Publication number Publication date
PL309975A1 (en) 1995-11-13
DE69409503D1 (de) 1998-05-14
JPH08505864A (ja) 1996-06-25
SK281229B6 (sk) 2001-01-18
JP3768232B2 (ja) 2006-04-19
AP9400613A0 (en) 1994-01-31
RU2129561C1 (ru) 1999-04-27
CZ187995A3 (en) 1996-01-17
NO952872L (no) 1995-09-13
CN1043997C (zh) 1999-07-07
NO952872D0 (no) 1995-07-19
KR960700261A (ko) 1996-01-19
US5925624A (en) 1999-07-20
PE54194A1 (es) 1995-01-06
IS4121A (is) 1994-07-21
HU211914A9 (en) 1996-01-29
ECSP941104A (es) 1994-12-15
TW267168B (OSRAM) 1996-01-01
EP0680488A1 (en) 1995-11-08
DE69409503T2 (de) 1998-08-06
FI953489A7 (fi) 1995-09-13
ZA94335B (en) 1994-10-24
AU5885194A (en) 1994-08-15
CA2153688A1 (en) 1994-08-04
ATE164849T1 (de) 1998-04-15
EP0680488B1 (en) 1998-04-08
SK91895A3 (en) 1996-04-03
FI953489L (fi) 1995-09-13
WO1994017090A1 (en) 1994-08-04
ES2117249T3 (es) 1998-08-01
CN1119440A (zh) 1996-03-27
FI953489A0 (fi) 1995-07-19
AP457A (en) 1996-02-01
DK0680488T3 (da) 1999-01-25
IL108372A0 (en) 1994-04-12
SI9400021A (en) 1994-09-30
US5889178A (en) 1999-03-30
AU679714B2 (en) 1997-07-10
GB9301000D0 (en) 1993-03-10
NZ259880A (en) 1996-11-26
NO305603B1 (no) 1999-06-28

Similar Documents

Publication Publication Date Title
AU679714B2 (en) 2,6-diaminopurine derivatives
RU2043361C1 (ru) Способ получения производных 2'-дезокси-2'-фторрибонуклеозидов или их фармацевтически приемлемых солей
US6448236B1 (en) Purine derivatives
WO1996002553A2 (en) AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES
US5668113A (en) Method of using 1,5-anhydrohexitol nucleoside analogues to treat viral infections
US5424295A (en) 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine
ES2324816T3 (es) Derivados de 2-aminocarbonil-9h-purina.
WO1996002543A1 (en) 2,3-dihydroxy cyclopentane derivatives of purines
WO2001027130A1 (en) Purine derivatives
EP2424546B1 (en) Method of reducing intraocular pressure in humans
KR20030036138A (ko) 퓨린 유도체
US6753322B2 (en) 2-aminocarbonyl-9H-purine derivatives
US20090048203A1 (en) Substituted adenines and the uses thereof
NO300461B1 (no) 2,6-Disubstituerte purinderivater
US5663154A (en) 2',3'-dideoxy-3'-fluoro-purine ribonucleosides
JPH0699467B2 (ja) ２▲’▼−デオキシ−２▲’▼（ｓ）−アルキルピリミジンヌクレオシド誘導体
CN101072787A (zh) 取代的腺嘌呤及其用途
HU205947B (en) Process for producing antiinfective nucleozides and pharmaceutical compositions containing them
JP2665527B2 (ja) ２’−デオキシ−２’−メチリデンピリミジンヌクレオチド化合物
EP0410660A1 (en) Cyclopentane derivatives
EP0418007A2 (en) Cyclopentane derivatives
HK1167599B (en) Method of reducing intraocular pressure in humans

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
FF Patent granted
KB Patent renewed
RH1 Patent not in force